Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05162443 |
|
Expanded Access Status :
Available
First Posted : December 17, 2021
Last Update Posted : January 20, 2022
|
Sponsor:
Mirati Therapeutics Inc.
Information provided by (Responsible Party):
Mirati Therapeutics Inc.
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Submitted Date | December 3, 2021 | ||||
| First Posted Date | December 17, 2021 | ||||
| Last Update Posted Date | January 20, 2022 | ||||
| Descriptive Information | |||||
| Brief Title | Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation | ||||
| Brief Summary | The objective of this EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation. | ||||
| Detailed Description | Not Provided | ||||
| Study Type | Expanded Access | ||||
| Expanded Access Type | Intermediate-size Population | ||||
| Intervention | Drug: adagrasib (MRTX849)
adagrasib (MRTX849) will be administered orally twice daily in a continuous regimen
|
||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Expanded Access Status | Available | ||||
| Contacts |
|
||||
| Listed Location Countries | United States | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number | NCT05162443 | ||||
| Current Responsible Party | Mirati Therapeutics Inc. | ||||
| Original Responsible Party | Same as current | ||||
| Current Study Sponsor | Mirati Therapeutics Inc. | ||||
| Original Study Sponsor | Same as current | ||||
| Collaborators | Not Provided | ||||
| Investigators | Not Provided | ||||
| PRS Account | Mirati Therapeutics Inc. | ||||
| Verification Date | January 2022 | ||||